-

Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced new preclinical data of its in vivo Gene Placement System (iGPS®) will be highlighted at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place on May 13-17, 2025, in New Orleans, Louisiana.

Details for the poster presentation are as follows:

ASGCT 28th Annual Meeting
Poster Title: Toward Treatment with Gene-Modified B Cells Engineered In Vivo Using iGPS Particles
Category: Cell Therapy: H2 – In-Vivo Editing of HSPCs and Immune Cells
Presenter: Russell McConnell, Ph.D., Director, Discovery Research at Kelonia
Date and Time: Wednesday, May 14, 5:30 – 7:00 p.m. CDT

About Kelonia Therapeutics

Kelonia is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS®). The company’s elegant, cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modifications to improve in vivo gene transfer efficiency and tropism molecules to facilitate tissue-specific delivery. Initially focused on developing transformational in vivo CAR-T therapies for hematologic cancers, Kelonia is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. Learn more about Kelonia at https://www.keloniatx.com/ and follow us on LinkedIn and X.

Contacts

Katherine Smith, Inizio Evoke Comms
katherine.smith@inizioevoke.com

Industry:

Kelonia Therapeutics, Inc.

Release Versions
English

Contacts

Katherine Smith, Inizio Evoke Comms
katherine.smith@inizioevoke.com

More News From Kelonia Therapeutics, Inc.

Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today shared positive updated results from inMMyCAR, the ongoing first-in-human Phase 1 study of KLN-1010 in patients with relapsed and refractory multiple myeloma (RRMM), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Fourteen additional patients have been dosed since first clinical data were reported at the American Societ...

Kelonia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KLN-1010, an in vivo BCMA CAR-T Therapy for Relapsed and Refractory Multiple Myeloma

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for KLN-1010 for the treatment of patients with relapsed and refractory multiple myeloma. KLN-1010 is a novel in vivo gene therapy designed to generate anti-BCMA CAR-T cells directly within patients following a single infusion, without the requireme...

Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today shared first-in-human data from the ongoing inMMyCARTM study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells in patients with relapsed and refractory multiple myeloma, in a late-breaking oral presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando, Florida. Highlights o...
Back to Newsroom